SA521430638B1 - H مركبات بيرميدين-2-يل أمينو-1 lrrk2 بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبية - Google Patents
H مركبات بيرميدين-2-يل أمينو-1 lrrk2 بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبيةInfo
- Publication number
- SA521430638B1 SA521430638B1 SA521430638A SA521430638A SA521430638B1 SA 521430638 B1 SA521430638 B1 SA 521430638B1 SA 521430638 A SA521430638 A SA 521430638A SA 521430638 A SA521430638 A SA 521430638A SA 521430638 B1 SA521430638 B1 SA 521430638B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- pyrazols
- ylamino
- pyrimidin
- treatment
- neurodegenerative disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662350876P | 2016-06-16 | 2016-06-16 | |
| US201662417151P | 2016-11-03 | 2016-11-03 | |
| US201762476581P | 2017-03-24 | 2017-03-24 | |
| US201762510711P | 2017-05-24 | 2017-05-24 | |
| PCT/US2017/037782 WO2017218843A1 (en) | 2016-06-16 | 2017-06-15 | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA521430638B1 true SA521430638B1 (ar) | 2023-07-12 |
Family
ID=59216078
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA521430638A SA521430638B1 (ar) | 2016-06-16 | 2018-12-13 | H مركبات بيرميدين-2-يل أمينو-1 lrrk2 بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبية |
| SA518400660A SA518400660B1 (ar) | 2016-06-16 | 2018-12-13 | مركبات بيرميدين-2-يل أمينو -1h- بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبيةlrrk2 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA518400660A SA518400660B1 (ar) | 2016-06-16 | 2018-12-13 | مركبات بيرميدين-2-يل أمينو -1h- بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبيةlrrk2 |
Country Status (37)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017087905A1 (en) | 2015-11-20 | 2017-05-26 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
| CA3025672A1 (en) | 2016-06-16 | 2017-12-21 | Denali Therapeutics Inc. | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders |
| AU2018372180B2 (en) | 2017-11-21 | 2023-08-17 | Denali Therapeutics Inc. | Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production |
| CN112088003B (zh) | 2017-12-20 | 2023-10-13 | 戴纳立制药公司 | 制备嘧啶基-4-氨基吡唑化合物的工艺 |
| KR20190131981A (ko) * | 2018-05-18 | 2019-11-27 | 재단법인 대구경북첨단의료산업진흥재단 | 외상성 뇌손상 또는 뇌졸중의 예방 또는 치료용 약학적 조성물 |
| AR118641A1 (es) * | 2019-04-11 | 2021-10-20 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
| KR20220015437A (ko) * | 2019-05-31 | 2022-02-08 | 데날리 테라퓨틱스 인크. | 피리미디닐아미노-피라졸 화합물의 변형 방출 제제, 및 치료 방법 |
| EP3769768A1 (en) | 2019-07-23 | 2021-01-27 | Consejo Superior de Investigaciones Cientificas (CSIC) | Compounds useful for the treatment of parkinson s disease |
| WO2021086966A1 (en) * | 2019-10-29 | 2021-05-06 | Biogen Ma Inc. | Spirocyclic o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
| KR102342803B1 (ko) | 2020-03-23 | 2021-12-24 | 환인제약 주식회사 | 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물 |
| CA3172750A1 (en) | 2020-03-23 | 2021-09-30 | Ge Hyeong Lee | Novel pyrimidine derivative, and composition for preventing or treating neurodegenerative diseases and cancer, comprising same |
| DK4225306T3 (da) * | 2020-10-07 | 2025-03-24 | Alzprotect | Anvendelse af n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-aminsulfatsalte og solvater heraf til behandling af motorneuronsygdomme og neuromuskulære forbindelseslidelser |
| AU2021371697B2 (en) * | 2020-10-29 | 2024-10-24 | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof |
| JP2024515885A (ja) * | 2021-04-30 | 2024-04-10 | デナリ セラピューティクス インコーポレイテッド | パーキンソン病を処置及びモニタリングするための方法 |
| WO2023073013A1 (en) | 2021-10-27 | 2023-05-04 | H. Lundbeck A/S | Lrrk2 inhibitors |
| MX2024007383A (es) | 2021-12-15 | 2024-08-28 | Whan In Pharmaceutical Co Ltd | Derivado de pirimidina macrocíclica, método para preparar el mismo y composición farmacéutica para prevención o tratamiento de una enfermedad neurodegenerativa que contiene el mismo como ingrediente activo. |
| CN117624185B (zh) * | 2022-08-23 | 2025-12-05 | 长春金赛药业有限责任公司 | Lrrk2抑制剂化合物、药物组合物及其制备方法和应用 |
| AR130483A1 (es) | 2022-09-15 | 2024-12-11 | H Lundbeck As | Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2) |
| CN120826397A (zh) | 2022-11-03 | 2025-10-21 | 戴纳立制药公司 | 嘧啶三唑化合物的固体及共晶体形式 |
| CN115894456A (zh) * | 2022-11-13 | 2023-04-04 | 药康众拓(江苏)医药科技有限公司 | 一种氘代吡唑氨基嘧啶类化合物、药物组合物和用途 |
| TW202434571A (zh) | 2022-11-22 | 2024-09-01 | 美商戴納立製藥公司 | 嘧啶胺基吡唑化合物之製備方法及中間物 |
| CN115819405A (zh) * | 2022-12-20 | 2023-03-21 | 沪渝人工智能研究院 | 嘧啶氨基吡唑衍生物及其作为富亮氨酸重复激酶2抑制剂的应用 |
| CN119968373A (zh) * | 2023-09-07 | 2025-05-09 | 上海翊石医药科技有限公司 | 一种芳杂环类化合物及其制备方法 |
| CN118878521B (zh) * | 2024-09-26 | 2025-02-14 | 苏州美诺医药科技有限公司 | 一种lrrk2抑制剂的制备方法 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2381600A (en) | 1998-12-23 | 2000-07-31 | Du Pont Pharmaceuticals Company | Thrombin or factor xa inhibitors |
| AU2002339230A1 (en) | 2002-03-08 | 2003-09-22 | Decode Genetics Ehf. | A susceptibility gene for late-onset idiopathic parkinson's disease |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| US7371759B2 (en) * | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| AR049418A1 (es) | 2004-02-27 | 2006-08-02 | Bayer Pharmaceuticals Corp | Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes. |
| EP1841760B1 (en) | 2004-12-30 | 2011-08-10 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| EP1746096A1 (en) | 2005-07-15 | 2007-01-24 | 4Sc Ag | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer |
| EP1999135A2 (en) | 2006-03-30 | 2008-12-10 | Takeda San Diego, Inc. | Kinase inhibitors |
| CA2657980A1 (en) | 2006-06-20 | 2007-12-27 | Novartis Ag | Biomarkers for the progression of alzheimer's disease |
| WO2008118822A1 (en) | 2007-03-23 | 2008-10-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| KR20090130141A (ko) | 2007-04-19 | 2009-12-17 | 노파르티스 아게 | 대사성 글루타메이트 수용체-5의 조절자로서의 니코틴산 유도체 |
| EP2152694A2 (en) | 2007-05-02 | 2010-02-17 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
| EP2164842A2 (en) | 2007-05-24 | 2010-03-24 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
| AU2008296479A1 (en) | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
| WO2009127642A2 (en) | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
| AR075713A1 (es) | 2009-03-03 | 2011-04-20 | Du Pont | Pirazoles fungicidas |
| WO2010111406A2 (en) | 2009-03-24 | 2010-09-30 | Myriad Pharmaceuticals, Inc. | Compounds and therapeutic uses thereof |
| TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| CN102811619B (zh) | 2009-11-13 | 2015-04-22 | 金纳斯克公司 | 激酶抑制剂 |
| GB201008134D0 (en) | 2010-05-14 | 2010-06-30 | Medical Res Council Technology | Compounds |
| JP5713367B2 (ja) | 2010-06-04 | 2015-05-07 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｌｒｒｋ２モジュレーターとしてのアミノピリミジン誘導体 |
| WO2011156698A2 (en) | 2010-06-11 | 2011-12-15 | Abbott Laboratories | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS |
| US9233977B2 (en) | 2010-10-29 | 2016-01-12 | Merck Sharp & Dohme Corp. | Leucine-rich repeat kinase enzyme activity |
| HUE037844T2 (hu) * | 2010-11-10 | 2018-09-28 | Genentech Inc | Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok |
| CA2818428A1 (en) | 2010-11-30 | 2012-06-07 | Genentech, Inc. | Assays and biomarkers for lrrk2 |
| EP2720719A4 (en) | 2011-06-15 | 2015-12-09 | Glaxosmithkline Ip No 2 Ltd | METHOD FOR SELECTION OF THERAPEUTIC INDICATIONS |
| BR112014000360A2 (pt) | 2011-07-28 | 2017-02-14 | Cellzome Ltd | análogos de heterociclil pirimidina como inibidores jak |
| EP2758402B9 (en) | 2011-09-22 | 2016-09-14 | Pfizer Inc | Pyrrolopyrimidine and purine derivatives |
| CA2850705C (en) | 2011-11-29 | 2020-03-10 | F. Hoffmann-La Roche Ag | 2-(phenyl or pyrid-3-yl)aminopyrimidine derivatives as kinase lrrk2 modulators for the treatment of parkinson's disease |
| CA2850594C (en) | 2011-11-29 | 2020-03-10 | F. Hoffmann-La Roche Ag | Aminopyrimidine derivatives as lrrk2 modulators |
| AR089182A1 (es) | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
| KR102002198B1 (ko) | 2011-11-29 | 2019-07-19 | 제넨테크, 인크. | Lrrk2 조절제로서의 아미노피리미딘 유도체 |
| CA2856002C (en) | 2011-11-30 | 2020-10-13 | Bryan K. Chan | Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2 |
| WO2013126283A1 (en) | 2012-02-20 | 2013-08-29 | E. I. Du Pont De Nemours And Company | Fungicidal pyrazoles |
| PL2820009T3 (pl) | 2012-03-01 | 2018-09-28 | Array Biopharma, Inc. | Inhibitory kinaz serynowo/treoninowych |
| MX358172B (es) * | 2012-05-03 | 2018-08-08 | Genentech Inc | Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson. |
| WO2013164321A1 (en) * | 2012-05-03 | 2013-11-07 | F. Hoffmann-La Roche Ag | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
| JP2016509602A (ja) | 2013-01-25 | 2016-03-31 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎の処置のためのスクアリン酸誘導体 |
| WO2014130241A1 (en) | 2013-02-20 | 2014-08-28 | E. I. Du Pont De Nemours And Company | Fungicidal pyrazoles |
| JP6409007B2 (ja) | 2013-03-05 | 2018-10-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 抗癌剤としての９−（アリールまたはヘテロアリール）−２−（ピラゾリル、ピロリジニルまたはシクロペンチル）アミノプリン誘導体 |
| EP2968995B1 (en) | 2013-03-15 | 2018-05-09 | Elan Pharmaceuticals LLC | Inhibitors of lrrk2 kinase activity |
| JP6553589B2 (ja) | 2013-03-15 | 2019-07-31 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | ピリミド−ジアゼピノン化合物および障害の治療方法 |
| TW201533043A (zh) * | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物 |
| WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| KR20160007577A (ko) | 2013-05-10 | 2016-01-20 | 카루스 떼라퓨틱스 리미티드 | 신규한 히스톤 디아세틸라제 억제제들 |
| EP3099695B1 (en) | 2014-01-29 | 2020-04-08 | GlaxoSmithKline Intellectual Property Development Limited | Compounds |
| CN107074861A (zh) | 2014-02-28 | 2017-08-18 | 密执安大学评议会 | 作为bet溴结构域抑制剂的9h嘧啶并[4，5‑b]吲哚和相关类似物 |
| US9399637B2 (en) | 2014-03-28 | 2016-07-26 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| DK3185868T3 (da) | 2014-08-25 | 2022-05-23 | Salk Inst For Biological Studi | Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme |
| CN105461694B (zh) | 2014-09-27 | 2019-05-24 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| AU2015357585B2 (en) | 2014-12-05 | 2020-07-02 | Array Biopharma Inc. | 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors |
| WO2016149311A1 (en) | 2015-03-19 | 2016-09-22 | E I Du Pont De Nemours And Company | Fungicidal pyrazoles |
| JP2018135268A (ja) | 2015-06-05 | 2018-08-30 | 大日本住友製薬株式会社 | 新規ヘテロアリールアミノ−３−ピラゾール誘導体およびその薬理学上許容される塩 |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| CN108137586B (zh) | 2015-09-14 | 2021-04-13 | 辉瑞大药厂 | 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物 |
| US9840710B2 (en) | 2015-11-18 | 2017-12-12 | Rosalind Franklin University Of Medicine And Science | Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease |
| WO2017087905A1 (en) | 2015-11-20 | 2017-05-26 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| TW201720828A (zh) | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
| WO2017100703A1 (en) | 2015-12-10 | 2017-06-15 | Colin Combs | Ems analogues of lyn/src-tyrosine kinase inhibitors |
| JP2018537502A (ja) | 2015-12-16 | 2018-12-20 | サウザーン リサーチ インスチチュート | ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法 |
| SG11201806302RA (en) * | 2016-02-05 | 2018-08-30 | Denali Therapeutics Inc | Inhibitors of receptor-interacting protein kinase 1 |
| US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
| CA3025672A1 (en) | 2016-06-16 | 2017-12-21 | Denali Therapeutics Inc. | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders |
| WO2018217946A1 (en) | 2017-05-24 | 2018-11-29 | Denali Therapeutics Inc. | Compounds, compositions and methods |
-
2017
- 2017-06-15 CA CA3025672A patent/CA3025672A1/en active Pending
- 2017-06-15 HR HRP20211923TT patent/HRP20211923T1/hr unknown
- 2017-06-15 KR KR1020237022665A patent/KR102705724B1/ko active Active
- 2017-06-15 ES ES21198102T patent/ES3036953T3/es active Active
- 2017-06-15 DK DK21198102.2T patent/DK3998261T3/da active
- 2017-06-15 UA UAA201812165A patent/UA126231C2/uk unknown
- 2017-06-15 SM SM20210699T patent/SMT202100699T1/it unknown
- 2017-06-15 EP EP17733306.9A patent/EP3472153B1/en active Active
- 2017-06-15 EP EP25174508.9A patent/EP4635570A2/en active Pending
- 2017-06-15 SG SG11201810579YA patent/SG11201810579YA/en unknown
- 2017-06-15 SI SI201731005T patent/SI3472153T1/sl unknown
- 2017-06-15 PL PL17733306T patent/PL3472153T3/pl unknown
- 2017-06-15 CN CN202111282850.1A patent/CN114315819A/zh active Pending
- 2017-06-15 KR KR1020247029993A patent/KR102843750B1/ko active Active
- 2017-06-15 IL IL299415A patent/IL299415B2/en unknown
- 2017-06-15 AU AU2017286653A patent/AU2017286653B2/en active Active
- 2017-06-15 IL IL299412A patent/IL299412B2/en unknown
- 2017-06-15 WO PCT/US2017/037782 patent/WO2017218843A1/en not_active Ceased
- 2017-06-15 EP EP21198102.2A patent/EP3998261B1/en active Active
- 2017-06-15 HU HUE17733306A patent/HUE056678T2/hu unknown
- 2017-06-15 MD MDE20190504T patent/MD3472153T2/ro unknown
- 2017-06-15 LT LTEPPCT/US2017/037782T patent/LT3472153T/lt unknown
- 2017-06-15 PE PE2018003221A patent/PE20190395A1/es unknown
- 2017-06-15 CR CR20180592A patent/CR20180592A/es unknown
- 2017-06-15 KR KR1020197000749A patent/KR102553188B1/ko active Active
- 2017-06-15 RS RS20211513A patent/RS62868B1/sr unknown
- 2017-06-15 CN CN201780036925.3A patent/CN109311857B/zh active Active
- 2017-06-15 SG SG10201912632YA patent/SG10201912632YA/en unknown
- 2017-06-15 US US15/624,566 patent/US20170362206A1/en not_active Abandoned
- 2017-06-15 ES ES17733306T patent/ES2900368T3/es active Active
- 2017-06-15 PE PE2023001478A patent/PE20240221A1/es unknown
- 2017-06-15 PT PT177333069T patent/PT3472153T/pt unknown
- 2017-06-15 MX MX2018015630A patent/MX392230B/es unknown
- 2017-06-15 CR CR20220182A patent/CR20220182A/es unknown
- 2017-06-15 TN TNP/2018/000422A patent/TN2018000422A1/en unknown
- 2017-06-15 CU CU2018000152A patent/CU24605B1/es unknown
- 2017-06-15 IL IL263484A patent/IL263484B2/en unknown
- 2017-06-15 JP JP2018565694A patent/JP7004459B2/ja active Active
- 2017-06-15 JO JOP/2018/0113A patent/JOP20180113B1/ar active
- 2017-06-16 TW TW106120263A patent/TWI786049B/zh active
- 2017-10-25 US US15/793,882 patent/US9932325B2/en active Active
-
2018
- 2018-03-21 US US15/927,920 patent/US10590114B2/en active Active
- 2018-11-19 PH PH12018502427A patent/PH12018502427A1/en unknown
- 2018-12-13 MX MX2022005610A patent/MX2022005610A/es unknown
- 2018-12-13 SA SA521430638A patent/SA521430638B1/ar unknown
- 2018-12-13 SA SA518400660A patent/SA518400660B1/ar unknown
- 2018-12-13 MX MX2021010304A patent/MX2021010304A/es unknown
- 2018-12-13 DO DO2018000285A patent/DOP2018000285A/es unknown
- 2018-12-14 CL CL2018003597A patent/CL2018003597A1/es unknown
- 2018-12-14 EC ECSENADI201892481A patent/ECSP18092481A/es unknown
- 2018-12-14 CO CONC2018/0013585A patent/CO2018013585A2/es unknown
-
2019
- 2019-01-14 ZA ZA2019/00229A patent/ZA201900229B/en unknown
-
2020
- 2020-03-13 US US16/818,745 patent/US11111235B2/en active Active
-
2021
- 2021-08-13 US US17/401,833 patent/US11591316B2/en active Active
- 2021-12-14 CY CY20211101098T patent/CY1124789T1/el unknown
-
2022
- 2022-04-08 AU AU2022202372A patent/AU2022202372B2/en active Active
- 2022-04-25 DO DO2022000088A patent/DOP2022000088A/es unknown
-
2023
- 2023-01-19 US US18/099,082 patent/US11834439B2/en active Active
- 2023-04-17 DO DO2023000077A patent/DOP2023000077A/es unknown
-
2024
- 2024-06-14 US US18/744,133 patent/US20250034119A1/en active Pending
- 2024-07-03 AU AU2024204621A patent/AU2024204621A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA521430638B1 (ar) | H مركبات بيرميدين-2-يل أمينو-1 lrrk2 بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبية | |
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| MY201438A (en) | Compounds, compositions and methods | |
| PH12017500583A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| MD20170016A2 (ro) | Compuşi aminopirimidinici ca inhibitori JAK | |
| PH12016501457B1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| PH12017500595B1 (en) | Aldosterone synthase inhibitors | |
| MY178971A (en) | Triaminopyrimidine compounds useful for preventing or treating malaria | |
| MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
| MX2020005707A (es) | Profarmacos de creatina, composiciones y metodos de uso de estos. | |
| EA201892532A1 (ru) | Пиримидин-2-иламино-1н-пиразолы в качестве ингибиторов lrrk2 для применения при лечении нейродегенеративных заболеваний | |
| MY183757A (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
| MY195679A (en) | Pyrimidin-2-Ylamino-1h-Pyrazols as Lrrk2 Inhibitors for use in the Treatment of Neurodegenerative Disorders | |
| NZ747201A (en) | (+)-azasetron for use in the treatment of ear disorders | |
| MX2023012107A (es) | Uso de piridostigmina para el tratamiento de covid-19. |